Patent Docket No: P5009R1

Amendments to the Claims:

Claims 1-15 are amended without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 (currently amended) An isolated antibody which binds to a polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10);
- (b) the amino acid sequence shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), lacking its associated signal peptide;
- (c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), with its associated signal peptide;
- (d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), lacking its associated signal peptide;
- (e) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:2), Figure 3 (SEQ ID NO:3), Figure 4 (SEQ ID NO:4), or Figure 5 (SEQ ID NO:5);
- (f) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:2), Figure 3 (SEQ ID NO:3), Figure 4 (SEQ ID NO:4), or Figure 5 (SEQ ID NO:5); or
- (g) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under any ATCC accession number 203127shown in Table 7.
- 2 (currently amended) The antibody of Claim 1 which binds to a polypeptide comprising:
- (a) the amino acid sequence shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10);
- (b) the amino acid sequence shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), lacking its associated signal peptide;

Appl. No. 09/938,418 Patent Docket No: P5009R1

(c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), with its associated signal peptide;

- (d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:6), Figure 7 (SEQ ID NO:7), Figure 8 (SEQ ID NO:8), Figure 9 (SEQ ID NO:9), or Figure 10 (SEQ ID NO:10), lacking its associated signal peptide;
- (e) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:2), Figure 3 (SEQ ID NO:3), Figure 4 (SEQ ID NO:4), or Figure 5 (SEQ ID NO:5);
- (f) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:2), Figure 3 (SEQ ID NO:3), Figure 4 (SEQ ID NO:4), or Figure 5 (SEQ ID NO:5); or
- (g) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under any-ATCC accession number 203127shown in Table 7.
 - 3 (original) The antibody of Claim 1 which is a monoclonal antibody.
 - 4 (original) The antibody of Claim 1 which is an antibody fragment.
 - 5 (original) The antibody of Claim 1 which is a chimeric or a humanized antibody.
- 6 (original) The antibody of Claim 1 which is conjugated to a growth inhibitory agent.
 - 7 (original) The antibody of Claim 1 which is conjugated to a cytotoxic agent.
- 8 (original) The antibody of Claim 7, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
 - 9 (original) The antibody of Claim 7, wherein the cytotoxic agent is a toxin.
- 10 (original) The antibody of Claim 9, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

Patent Docket No: P5009R1

15 (original)

11 (original)	The antibody of Claim 9, wherein the toxin is a maytansinoid.
12 (original)	The antibody of Claim 1 which is produced in bacteria.
13 (original)	The antibody of Claim 1 which is produced in CHO cells.
14 (original)	The antibody of Claim 1 which induces death of a cell to which it binds.

The antibody of Claim 1 which is detectably labeled.